Literature DB >> 17223219

New perspectives for the treatment of cholestasis: lessons from basic science applied clinically.

James L Boyer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17223219      PMCID： PMC1847591          DOI： 10.1016/j.jhep.2006.12.001

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  78 in total

1.  Identification and functional characterization of the promoter region of the human organic anion transporting polypeptide gene.

Authors:  G A Kullak-Ublick; U Beuers; C Fahney; B Hagenbuch; P J Meier; G Paumgartner
Journal:  Hepatology       Date:  1997-10       Impact factor: 17.425

2.  Rifampin relieves pruritus in children with cholestatic liver disease.

Authors:  H A Cynamon; J M Andres; R P Iafrate
Journal:  Gastroenterology       Date:  1990-04       Impact factor: 22.682

3.  Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis.

Authors:  J M de Vree; E Jacquemin; E Sturm; D Cresteil; P J Bosma; J Aten; J F Deleuze; M Desrochers; M Burdelski; O Bernard; R P Oude Elferink; M Hadchouel
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

4.  Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis.

Authors:  L Bachs; A Parés; M Elena; C Piera; J Rodés
Journal:  Lancet       Date:  1989-03-18       Impact factor: 79.321

5.  Phenobarbital effects in cholestatic liver diseases.

Authors:  J R Bloomer; J L Boyer
Journal:  Ann Intern Med       Date:  1975-03       Impact factor: 25.391

6.  Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice.

Authors:  Mahfoud Assem; Erin G Schuetz; Markos Leggas; Daxi Sun; Kazuto Yasuda; Glen Reid; Noam Zelcer; Masashi Adachi; Stephen Strom; Ronald M Evans; David D Moore; Piet Borst; John D Schuetz
Journal:  J Biol Chem       Date:  2004-03-05       Impact factor: 5.157

7.  Stimulation of bile acid 6 alpha-hydroxylation by rifampin.

Authors:  H Wietholtz; H U Marschall; J Sjövall; S Matern
Journal:  J Hepatol       Date:  1996-06       Impact factor: 25.083

8.  Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial.

Authors:  C N Ghent; S G Carruthers
Journal:  Gastroenterology       Date:  1988-02       Impact factor: 22.682

9.  National Cooperative Gallstone Study: the effect of chenodeoxycholic acid on lipoproteins and apolipoproteins.

Authors:  J J Albers; S M Grundy; P A Cleary; D M Small; J M Lachin; L J Schoenfield
Journal:  Gastroenterology       Date:  1982-04       Impact factor: 22.682

10.  Chenodeoxycholic acid and ursodeoxycholic acid effects in endogenous hypertriglyceridemias. A controlled double-blind trial.

Authors:  N Carulli; M Ponz de Leon; M Podda; M Zuin; A Strata; G Frigerio; A Digrisolo
Journal:  J Clin Pharmacol       Date:  1981-10       Impact factor: 3.126
View more
  25 in total

Review 1.  Getting the mOST from OST: Role of organic solute transporter, OSTalpha-OSTbeta, in bile acid and steroid metabolism.

Authors:  Paul A Dawson; Melissa L Hubbert; Anuradha Rao
Journal:  Biochim Biophys Acta       Date:  2010-06-09

2.  Liver-specific β-catenin knockout mice have bile canalicular abnormalities, bile secretory defect, and intrahepatic cholestasis.

Authors:  Tzu-Hsuan Yeh; Lindsay Krauland; Vijay Singh; Baobo Zou; Prathab Devaraj; Donna B Stolz; Jonathan Franks; Satdarshan P S Monga; Eizaburo Sasatomi; Jaideep Behari
Journal:  Hepatology       Date:  2010-10       Impact factor: 17.425

3.  Triggering receptor in myeloid cells (TREM-1) specific expression in peripheral blood mononuclear cells of sepsis patients with acute cholangitis.

Authors:  Rui Liao; Zuojin Liu; Sidong Wei; Faliang Xu; Zhenzhen Chen; Jianping Gong
Journal:  Inflammation       Date:  2009-06       Impact factor: 4.092

4.  p53-mediated regulation of bile acid disposition attenuates cholic acid-induced cholestasis in mice.

Authors:  Pan Chen; Dongshun Li; Yixin Chen; Jiahong Sun; Kaili Fu; Lihuan Guan; Huizhen Zhang; Yiming Jiang; Xi Li; Xuezhen Zeng; Xiao Chen; Min Huang; Huichang Bi
Journal:  Br J Pharmacol       Date:  2017-10-22       Impact factor: 8.739

5.  Evaluation of the protective effect of Rhei Radix et Rhizoma against α-naphthylisothiocyanate induced liver injury based on metabolic profile of bile acids.

Authors:  Fan Yang; Ying Xu; Aizhen Xiong; Yugi He; Li Yang; Yu-Jui Yvonne Wan; Zhengtao Wang
Journal:  J Ethnopharmacol       Date:  2012-10-08       Impact factor: 4.360

Review 6.  Organic solute transporter, OSTalpha-OSTbeta: its role in bile acid transport and cholestasis.

Authors:  Carol J Soroka; Nazzareno Ballatori; James L Boyer
Journal:  Semin Liver Dis       Date:  2010-04-26       Impact factor: 6.115

7.  Ostα depletion protects liver from oral bile acid load.

Authors:  Carol J Soroka; Heino Velazquez; Albert Mennone; Nazzareno Ballatori; James L Boyer
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-06-30       Impact factor: 4.052

8.  Organic anion transporting polypeptide 1a1 null mice are sensitive to cholestatic liver injury.

Authors:  Youcai Zhang; Iván L Csanaky; Xingguo Cheng; Lois D Lehman-McKeeman; Curtis D Klaassen
Journal:  Toxicol Sci       Date:  2012-03-29       Impact factor: 4.849

9.  Mouse organic solute transporter alpha deficiency enhances renal excretion of bile acids and attenuates cholestasis.

Authors:  Carol J Soroka; Albert Mennone; Lee R Hagey; Nazzareno Ballatori; James L Boyer
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

10.  Nuclear factor erythroid 2-related factor 2 is a positive regulator of human bile salt export pump expression.

Authors:  Jittima Weerachayaphorn; Shi-Ying Cai; Carol J Soroka; James L Boyer
Journal:  Hepatology       Date:  2009-11       Impact factor: 17.425
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.